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INTRODUCTION
Sentinel lymph node biopsy (SLNB) is a standard procedure 
for axillary staging in clinically node-negative breast cancer 
patients. Several clinical trials have documented that there 
are no statistical differences in survival or regional lymph 
node (LN) recurrence between patients undergoing SLNB 
and those undergoing axillary LN dissection (ALND) [1-4]. 
Additionally, these studies provide evidence that SLNB offers 
accurate information about axillary nodal status, and it is less 
invasive. The results of the International Breast Cancer Study 
Group 23-01 study indicated that further axillary surgery was 
not necessary when only micrometastasis was seen in the 
sentinel lymph node (SLN) [5]. Furthermore, after the American 
College of Surgeons Oncology Group Z0011 study, the criteria 
for performing ALND were relaxed for patients who had one or 
two metastatic SLNs and were scheduled for breast conserving 
surgery, adjuvant chemotherapy, and adjuvant radiation therapy 
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Purpose: Sentinel lymph node (SLN) biopsy (SLNB) is widely performed for axillary staging in patients with breast cancer. 
Based on the results of frozen section examination (FSE), surgeons can decide to continue further axillary dissections. This 
study aimed to verify the accuracy of FSE for SLNs. 
Methods: We reviewed the records of 4,219 patients who underwent SLNB for primary invasive breast cancer between 
2007 and 2016 at the Severance Hospital. We evaluated factors associated with the false-negative results of FSE for SLNs 
using the Generalized Estimating Equations model. 
Results: A total of 1,397 SLNs from 908 patients were confirmed to be metastatic. Seventy-one patients (1.7%) had 
confirmed pathologic N2 or N3 stage. Among metastatic SLNs, micrometastasis was found in 234 (16.8%). The overall 
accuracy of SLNB was 98.5%. The sensitivity and false-negative rate of FSE were 86.4% and 13.6%, respectively. Several 
clinicopathological factors, including the size of SLN metastases, suspicious preoperative axillary lymph nodes, and 
luminal B subtype, were associated with a higher rate of false-negative results. 
Conclusion: Most patients were not indicated for axillary lymph node dissection. Some patients may show transition in their 
permanent pathology due to the size of the metastatic node. However, the false-negative results of FSE for SLNs based on 
the size of the metastatic node did not change our practice. Therefore, intraoperative FSE for SLN should not be routinely 
performed for all breast cancer patients.
[Ann Surg Treat Res 2019;97(2):49-57]
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[6]. The use of SLNB in patients with breast cancer can improve 
their quality of life by reducing postoperative side effects. 
Therefore, SLNB is extensively used and studied. 
Frozen section examination is a method for the intraoperative 
evaluation of SLNs. This modality enables single-stage surgery 
for immediate ALND when metastases are found in the SLNs 
and may help avoid additional axillary surgery [7]. ALND is still 
recommended for patients with positive SLNs who do not fulfill 
the Z0011 criteria. Additionally, frozen section examination 
provides immediate axillary nodal status for patients for 
whom imaging findings and preoperative pathologic results 
are discordant. Frozen section examinations can be performed 
for patients who desire immediate reconstruction following 
total mastectomy to avoid a second surgery. Thus, this mo-
dality continues to be a valuable assessment technique to 
facilitate decisions regarding additional ALND. However, 
frozen section examination is a limited diagnostic procedure 
and is less accurate than permanent section examination [8]. 
Reported false-negative rates of intraoperative frozen section 
examination for breast cancer range from 9%–59% [7,9]. False-
negative results for SLNs are the most common form of 
inaccurate result, primarily due to the size of the metastatic 
foci, but the accuracy of frozen section examination can be 
influenced by many factors during intraoperative evaluation 
[10-14]. Therefore, to avoid either confusion in interpreting 
frozen section examination results or disastrous harm to 
patients, frozen section examination results should be studied 
in light of the potential for false-negative results for SLNs.
Most previous studies that reported false-negative rates for 
frozen section examination used a logistic regression model 
to identify relationships between the response and predictive 
variables by generalization of the clinicopathological findings 
associated with metastatic SLNs. Additionally, previous studies 
neglected the fact that retrieved SLNs were correlated because 
they belonged to a single patient. A single patient could have 
one false-negative result or multiple false-negative results, 
and these findings should be viewed differently. The results 
of frozen section examination from a single patient would 
be more closely correlated than those from multiple patients; 
therefore, ignoring these correlations could result in bias [15]. 
It is important to adopt appropriate regression models that can 
analyze correlated data. Such regression models include mixed 
effect regression and generalized estimation equation (GEE) [16]. 
The use of mixed effect regression is suitable for continuous 
outcome variables, whereas GEE may be used for variables 
assessing other types of outcomes [17]. Therefore, we used GEE 
to evaluate factors related to false-negative results of SLNB in 
cases where several SLNs were present in the same patient and 
to observe variables that might have a possible, yet hitherto 
unknown, correlation.
This study aimed to evaluate the diagnostic performance 
of frozen section examination for SLN by analyzing the 
clinicopathological characteristics and treatment-related 
variables in patients with primary invasive breast cancer. 
METHODS
Patient selection
Patients with primary breast cancer who underwent SLNB 
between January 2007 and December 2016 were retrospectively 
selected from the medical database of the Yonsei University 
Severance Hospital (Seoul, Korea). Among 5,897 patients, 
patients receiving neoadjuvant chemotherapy (n = 612), 
patients with carcinoma in situ (n = 943), patients with 
axillary LN metastasis con firmed by preoperative fine needle 
aspiration, patients who received neoadjuvant chemotherapy (n 
= 118), and patients with missing data (n = 5) were excluded. 
A total of 4,219 patients with primary invasive breast cancer 
who underwent breast conserving surgeries or mastectomies 
with SLNB with or without ALND were included in this 
study. The medical database contained the clinicopathological 
characteristics of all patients, including their chief complaints, 
physical examinations, preoperative imaging evaluation 
findings (mammography, ultrasonography, magnetic resonance 
imaging, and positron emission tomography-computed 
tomography), treatment methods, and pathologic reports. This 
study was conducted in accordance with the Declaration of 
Helsinki, and was approved by the Institutional Review Board 
of the Severance Hospital, Yonsei University Health System 
(2017-1804-001).
Evaluation of SLNs and ALND policy 
SLNs were detected using a technetium-99m sulfur colloid 
diluted in normal saline. SLNs with counts greater than 10% 
of the most radioactive node were identified as “hot” nodes. 
Clinically suspicious palpable nodes in the surgical field 
were also resected as SLNs. The hot nodes detected by SLN 
mapping were labeled as radioactive SLNs in descending order 
of radioactive intensity, and suspicious cold nodes detected by 
palpation alone were labeled as clinical SLNs. The specimens 
were delivered to the Department of Pathology for generating 
frozen sections. The technicians removed the adipose tissue and 
sliced along the long axis of the LN. Two frozen section levels 
were examined by one breast-specialized pathologist and one 
trainee. The remaining unfrozen tissues were fixed in formalin 
and embedded in paraffin. Serial sections were stained with 
hematoxylin and eosin (H&E) and used for routine pathological 
examination as permanent sections. Immunohistochemistry 
(IHC) analysis of cytokeratin was used only if cells suspected 
to be metastases were seen on H&E-stained sections. LNs were 
considered metastatic if the metastatic foci were greater than 0.2 
mm, as described in the American Joint Committee on Cancer 
 Annals of Surgical Treatment and Research 51
(AJCC) staging manual, 8th edition [18]. Isolated tumor cells, 
defined as tumor foci measuring up to 0.2 mm, were considered 
nonmetastases. Metastases were classified as micrometastases 
or macrometastases, based on a threshold size of 2 mm for 
the metastatic deposits. ALND was performed based on the 
surgeon’s preference. In this retrospective study period, many 
surgeons applied ALND when the SLN was positive, even after 
publication of the Z0011 trial. 
Histopathologic characteristics
Postoperative pathologic stage was classified based on the 
AJCC staging, 8th edition [18]. Histologic grade was assessed 
using the modified Bloom-Richardson grading system. The 
tubule formation, nuclear pleomorphism, and mitotic counts 
were each assigned scores ranging from 1 to 3 points. The 
scores for these 3 criteria were added to yield an overall final 
score [19]. Tumors were considered positive for the estrogen 
receptor (ER) and the progesterone receptor (PR) with ≥1% 
nuclear-stained cells [20]. Human epidermal growth factor 
receptor 2 (HER2) status was scored from 0 to 3+, according to 
the American Society of Clinical Oncology/College of American 
Pathologists guidelines [21]. In cases with a HER2 status of 
2+, in situ hybridization (ISH) was performed, and HER2 
amplification was defined as a HER2 gene/chromosome 17 copy 
number ratio of >2.0. The HER2 status was considered positive 
in cases with IHC scores of 3+ and in those that showed gene 
amplification by ISH. On the basis of the ER, PR, and HER2 
findings, the molecular subtypes were categorized into 4 
subgroups as follows: luminal A: ER- or PR-positive, or both, 
and HER2-negative; luminal B: ER- or PR-positive, or both, and 
HER2-positive or more than 14% Ki-67; HER2-enriched: ER- and 
PR-negative and HER2-positive; and triple-negative breast cancer 
(TNBC): ER- PR-, and HER2-negative.
Data and statistical analysis
The variables for suspicious findings in the axillary LNs 
(ALNs) included the presence of a palpable mass in the axillary 
area on physical examination and suspicious findings in 
the axillary area during preoperative imaging studies. Most 
patients who had suspicious preoperative findings in the 
ALNs underwent ALN biopsy by fine needle aspiration. Our 
cohort included only patients with negative results after fine 
needle aspiration. During SLNB, dissection was performed in 
the fat tissue to minimize damage to the SLNs. In some cases, 
only lymphatic channels that showed radioisotope uptake 
were resected with bulky fat tissue, and they were sent to 
the pathology department. In some specimens, LNs were not 
reported in frozen section examination results. Additionally, 
the technician may have improperly classified specimens 
containing 2 or more SLNs while generating the frozen sections. 
Therefore, in some cases, the number of retrieved LNs reported 
in the frozen section examination were different from those 
reported in the permanent section examination. Occasionally, 
the frozen section examination results indicated the presence 
of atypical cells. The findings of these atypical cells were 
equivocal and they were difficult to designate as non-metastatic 
LNs or metastatic LNs. Atypical cells on frozen section 
examination results were considered non-metastatic LNs. 
False-negative results were defined as SLNs in which micro- 
and/or macrometastasis were not found in the frozen section 
examination, but which subsequently showed metastasis 
on permanent section examination (i.e., only cases in which 
metastasis was found in the deeper, permanent section 
but not in the frozen section). Sensitivity was calculated by 
dividing the true-positive (TP) SLN results by the TP plus false-
negative results. The negative predictive value was calculated 
by dividing the true-negative (TN) results by the TN plus false-
negative results. Accuracy was defined as the proportion of 
patients with TP or TN results among patients with successful 
SLNBs. We divided the patients into 2 groups according to the 
accuracy of their frozen section examination, namely, the false-
negative group and the accurate frozen section examination 
group. Differences between these groups were evaluated using 
the chi-square test or Fisher exact test. While performing the 
SLNBs, several LNs from the same patient were resected. The 
clinical information on the SLNs was based on repeatedly 
measured data. Therefore, the GEE model was used to explore 
the parameters associated with the false-negative rates based 
on each SLN. All statistical tests were 2-sided, and P < 0.05 was 
considered significant. SAS ver. 9.4 (SAS Institute, Cary, NC, 
USA) was used for the analysis. 
RESULTS 
Diagnostic performance of frozen section 
examination
A total of 12,422 SLN biopsies were performed in 4,219 
patients. A total of 1,397 SLNs from 908 patients were 
confirmed to be metastatic based on the pathologic reports of 
permanent section examinations. By comparing the results of 
frozen section examination with those of permanent section 
examination, it was observed that there were 11,025 TN, 1,207 
TP, and 190 false-negative results. The diagnostic performance 
of frozen section examination for SLNB is summarized in Table 1. 
A total of 190 diagnoses of SLNs in 173 patients were changed 
from non-metastatic to metastatic based on the permanent 
pathologic results. One hundred fifty-nine patients had only 
one false-negative result; the remaining 14 had 2 or more false-
negative results. No patients underwent ALND without ALN 
metastasis, owing to the high specificity of frozen section 
examination. Because of the false-negative results of frozen 
section examination, 130 patients underwent secondary ALND. 
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Characteristics of patients
The mean age of the patients at the time of surgery was 51.8 
years (standard deviation, 10.83). The mean number of retrieved 
SLNs was 2.73 (standard deviation, 1.52). Clinicopathological 
characteristics of the patients are shown in Table 2. The number 
of retrieved SLNs, number of positive SLNs, suspicious findings 
in ALNs, number of neoplastic foci, operation type, histology, 
lymphovascular invasions, TNM stage, ER positivity, and HER2 
amplification were significantly different between the 2 groups. 
Additionally, there were more patients with high TNM stage 
in the false-negative group than in the accurate frozen section 
examination group.
Prediction of false-negative results of frozen section 
examinations 
Several variables were significantly associated with false-
negative results on univariate analysis (Table 3). Treatment-
related variables, including number of metastatic SLNs, missed 
targeting by the surgeon during SLNB, and missed sampling 
by the technician during the generation of frozen sections, 
as well as clinicopathological factors, including suspicious 
findings in the ALNs, size of SLN metastases, atypical cells on 
frozen section examination, radioisotope uptake, luminal B 
subtype, and TNBC subtype, were associated with the false-
negative rate. Although most variables were associated with 
a higher false-negative rate, TNBC subtype was less likely to 
be associated with false-negative results (odds ratio, 0.3; P = 
0.001). The number of positive SLNs, presence of atypical cells 
on frozen section examination, SLN size, radioisotope uptake, 
suspicious findings in the ALNs, and luminal B subtype were 
associated with false-negative results on multivariate analysis. 
The presence of suspicious findings in the ALNs increased the 
incidence of false-negative results by 2.36 times on multivariate 
analysis. 
Characteristics and performance by subgroup
We performed subgroup analysis of several specific 
parameters associated with the diagnostic performance of 
frozen section examination. When analyzing by molecular 
subtype (Table 4), the frozen section examination of SLNs was 
most accurate in the TNBC subtype and least accurate in the 
luminal B subtype. The mean number of SLNs resected during 
intraoperative assessment was similar between subtypes. 
However, the mean positive LN counts were lowest in the TNBC 
subtype. The incidence of preoperative suspicious ALN findings 
was higher in the TNBC subtype than in the luminal B subtype. 
In contrast, the proportion of patients with pathological stage 
greater than N1 was higher in the luminal B subtype than in 
the TNBC subtype. We also performed subgroup analysis in 29 
patients with atypical cells in the frozen section examination 
(Table 5). Invasive lobular carcinomas (ILCs) were present in a 
significantly larger proportion of patients with atypical cells 
than in those without. Additionally, the size of the primary 
tumor was larger in patients with atypical cells than in those 
without. 
DISCUSSION
This study determined the diagnostic performance of in-
traoperative frozen section examination for SLNs and the 
factors associated with false-negative results. It is important to 
evaluate ALN status in patients with breast cancer to determine 
the disease stage, aid decisions for additional treatment after 
surgery, and predict prognosis. Intraoperative frozen sections 
have been used in several institutions because they confer the 
benefit of single-stage surgery for patients who require ALND. 
However, frozen section examination for ALN assessment 
may yield false-negative results. Therefore, it is necessary to 
understand the factors associated with false-negative results 
during frozen section examination.
In some studies, only one representative SLN was selected 
and analyzed. We were able to analyze the repeatedly measured 
data using a GEE model. In addition to the clinicopathological 
characteristics, our data also included surgical variables. 
Table 1. The diagnostic performance of frozen section examination according to the number of SLNBs performed
No. of times 
SLNB 
Patients,  
n (%)
Metastatic 
SLNa)
Mi.b),  
n (%)
Underesti­
mationc) FN SLN
d) Mi. of FN,  
n (%) 
Sensitivity 
(%)
NPV  
(%) 
FNR  
(%)
TA  
(%)
1, 2 2,147 (50.8) 264 57 (21.6) 4 33 20 (60.6) 87.5 99.9 12.5 99.1
3, 4 1,434 (33.9) 531 100 (18.8) 6 74 42 (56.8) 86.1 94.2 13.7 95.7
≥5  638 (15.3) 602 77 (12.8) 8 83 25 (30.1) 86.2 97.5 13.8 97.8
Total 4,219 (100) 1,397 234 (16.8) 18 190 87 (45.8) 86.4 98.3 13.6 98.5
SLNB, sentinel lymph node biopsy; SLN, sentinel lymph node; Mi., micrometastatic SLN; FN, false­negative results; NPV, negative 
predictive value; FNR, false­negative rate; TA, total accuracy.
a)Results of permanent section examination. b)Total number of micrometastatic sentinel lymph nodes and proportion. c)Total number of 
sentinel lymph nodes reported as “micrometastasis” during frozen section examination that were changed to “macrometastasis” in the 
permanent section examination. d)Total number of sentinel lymph nodes reported “free from tumor” during the frozen section 
examination that were changed to “metastasis” in the permanent section examination.
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Table 2. Clinicopathological characteristics associated with false­negative results of sentinel lymph node biopsy (n = 4,219)
Variable Accurate FSE group (n = 4,046) False negative group (n = 173) P­value
Age (yr) 51.86 ± 10.83 50.61 ± 9.58 0.136
Retrieved SLN count 2.73 ± 1.52 4.25 ± 1.86 <0.001
Positive SLN count 0.21 ± 0.54 1.30 ± 0.73 <0.001
ALN suspicious finding 0.021
   ALN suspicious finding (­) 3,301 (81.6) 129 (74.6)
   ALN suspicious finding (+) 745 (18.4) 44 (25.4)
Tumor location 0.182
   Upper outer quadrant 2,171 (53.7) 85 (49.1)
   Upper inner quadrant 827 (20.4) 31 (17.9)
   Lower outer quadrant 428 (10.6) 23 (13.3)
   Lower inner quadrant 190 (4.7) 7 (4.0)
   Sub areolar area 430 (10.6) 27 (15.6)
Number of neoplastic foci 0.026
   Unifocality 3,789 (93.6) 154 (89.0)
   Multifocality/multicentricity 257 (6.4) 19 (11.0)
Operation type <0.001
   BCS 2,433 (60.1) 82 (47.4)
   Mastectomy 1,613 (39.9) 91 (52.6)
Histology 0.034
   IDC 3,411 (84.3) 148 (85.5)
   ILC 195 (4.8) 14 (8.1)
   Other type of carcinoma 440 (10.9) 11 (6.4)
Histological grade 0.977
   G1 (well differentiation) 1,051 (26.0) 45 (26.0)
   G2 (mod differentiation) 2,079 (51.4) 90 (52.0)
   G3 (poor differentiation) 916 (22.6) 38 (22.0)
Lymphovascular invasion <0.001
   LVI (­) 3,750 (92.7) 140 (80.9)
   LVI (+) 296 (7.3) 33 (19.1)
Pathological T stage <0.001
   T1 (≤2 cm) 3,063 (75.7) 100 (57.8)
   T2 (>2 cm, ≤5 cm) 953 (23.6) 67 (38.7)
   T3 (>5 cm) 30 (0.7) 6 (3.5)
Pathological N stage <0.001
   N0 3,311 (81.8) 0 (0)
   N1mi 143 (3.5) 80 (46.2)
   N1a, b, c 531 (13.1) 83 (48.0)
   N2 58 (1.4) 8 (4.6)
   N3 3 (0.1) 2 (1.2)
TNM stage <0.001
   I 2,721 (67.3) 45 (26.0)
   II 1,249 (30.9) 112 (64.8)
   III 76 (1.9) 16 (9.2)
ER 0.005
   ER (­) 981 (24.2) 26 (15.0)
   ER (+) 3,065 (75.8) 147 (85.0)
HER2 amplification 0.182
   HER2 amplification (­) 3,123 (77.2) 126 (72.8)
   HER2 amplification (+) 923 (22.8) 47 (27.2)
Biological subtype <0.001
   Luminal A 2,163 (53.5) 103 (59.5)
   Luminal B 989 (24.4) 56 (32.4)
   Her2 enriched 337 (8.3) 9 (5.2)
   TNBC 557 (13.8) 5 (2.9)
Values are presented as mean ± standard deviation or number (%). 
FSE, frozen section examination; BCS, breast­conserving surgery; SLN, sentinel lymph node; ALN, axillary lymph node; BCS, breast conserving 
surgery; IDC, invasive ductal carcinoma; ILC, Invasive lobular carcinoma; LVI, lymphovascular invasion; ER, estrogen receptor; HER2, human 
epidermal growth factor receptor 2; TNBC, triple­negative breast cancer.
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Therefore, we could accurately analyze the false-negative result 
of the frozen section examination of each SLN. However, there 
are some limitations to our study. This was a retrospective 
study; therefore, a selection bias may have been present.
The false-negative rate increased with the number of resected 
SLNs. On logistic regression, the number of retrieved LNs 
did not influence the false-negative rate. However, as SLNBs 
are repeated, the probability of false-negative results in each 
assessment may cumulatively increase. In some cases, atypical 
cells were observed in frozen sections. This may have been 
related to inflammation of the LNs or structural changes 
that occurred during frozen section generation [22]. Atypical 
cells may also be seen in ILCs [23], as nodal involvement is a 
single-cell infiltration of the LN parenchyma, and it mimics 
a sinus histiocyte in ILCs [22,23]. The proportion of patients 
with ILC was high among patients with atypical cells in the 
frozen section examination. This may be due to the metastatic 
pattern of ILC. Lymphatic metastasis may modify or block the 
lymphatic channel [24]. In such cases, there may be a shift in 
the axillary mapping results. Therefore, in addition to the LNs 
detected in the mapping method, hard or large LNs may be 
metastatic. These cold LNs need to be evaluated for metastasis. 
The comparison of the diagnostic performance of frozen 
section examination of SLNs at our institution with those 
at other institutions suggests that the procedure is feasible 
[8,14,25,26]. Proper interpretation of the results of intraoperative 
Table 3. Univariate and multivariate analyses of the predictive variables of false­negative results of FSE
Variable
Univariate Multivariate
OR (95% CI) P­value OR (95% CI) P­value
Retrieved SLN count  1.17 (0.96–1.42) 0.124  
Positive SLN count 4.12 (2.81–5.99) <0.001 4.37 (2.99–6.41) <0.001
presence of LN on specimen
   LN presence reference reference
   LN absence  1.72 (1.26–2.32) 0.006  1.61 (0.31–8.37) 0.575
Sampling miss on FS production 
   Success reference reference
   Fail 2.72 (0.13–13.43) 0.011  1.35 (0.21–8.83) 0.476
Atypical cell on FSE
   Atypical cell (­) reference reference
   Atypical cell (+) 7.02 (5.51–12.66) <0.001 5.48 (1.31–17.88) <0.001
SLN size 
   Micrometastasis (>0.2 mm, ≤2 mm) 9.45 (6.55–11.52) <0.001  7.11 (6.39–9.83) <0.001
   Macrometastasis (>2 mm) reference reference
Radioisotope uptake
   Hot node reference reference
   Cold node 7.27 (4.19–12.62) <0.001 2.17 (1.16–4.05) 0.017
ALN suspicious finding
   ALN suspicious finding (­) reference reference
   ALN suspicious finding (+) 3.72 (1.75–8.48) <0.001  2.36 (1.25–4.46) 0.008
ER
   ER (­) reference
   ER (+) 1.72(0.65–4.51) 0.273
HER2 amplification
   HER2 amplification (­) reference
   HER2 amplification (+) 1.41(0.63–3.14) 0.402
Biological subtype
   Luminal A reference reference
   Luminal B  2.25 (1.56–3.23) <0.001  1.71 (1.08–4.91) 0.029
   Her2 enriched  0.65 (0.33–1.28) 0.212  0.54 (0.03–1.71) 0.212
   TNBC  0.3 (0.14–0.61) 0.001  0.21 (0.17–1.04) 0.061
FSE, frozen section examination; OR, odds ratio; CI, confidence interval; SLN, sentinel lymph node; LN, lymph node; FS, frozen 
section; ALN, axillary lymph node; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple­negative 
breast cancer.
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Table 4. Characteristics and performance of SLNB by molecular subtype
Variable
Luminal A
(n = 2,266)
Luminal B
(n = 1,045)
Her2 enriched
(n = 346)
TNBC
(n = 562)
P­value
Sensitivity (%) 85.3 82.7 89.6 93.8
NPV (%) 98.1 97.5 98.8 99.7
FNR (%) 14.7 17.3 10.4 6.3
TA (%) 98.3 97.7 98.9 99.7
Retrieved SLN count 2.84 ± 1.64 2.71 ± 1.51 2.82 ± 1.41 2.78 ± 1.45 0.183
Metastatic SLN count 0.33 ± 0.78 0.35 ± 0.69 0.31 ± 0.69 0.14 ± 0.49 <0.001
FSE results <0.001
   Accurate FSE 2,163 (95.5) 989 (94.6) 337 (97.4) 557 (99.1)
   False negative 103 (4.5) 56 (5.4) 9 (2.6) 5 (0.9)
ALN suspicious finding <0.001
   ALN suspicious finding (­) 1,971 (87.1) 806 (77.1) 245 (70.8) 408 (72.6)
   ALN suspicious finding (+) 295 (12.9) 239 (22.9) 101 (29.2) 154 (27.4)
Pathological N stage <0.001
   N0 1,781 (78.6) 769 (73.6) 275 (79.5) 505 (89.9)
   ≥N1  485 (21.4) 276 (26.4)  71 (20.5)  57 (10.1)
Histology <0.001
   IDC 1,795 (79.2) 947 (90.6) 330 (95.4) 487 (86.7)
   ILC  167 (7.4)  33 (3.2)  3 (0.9)  6 (1.1)
   Other type of carcinoma  304 (13.4)  65 (6.2) 15 (4.3) 69 (12.3)
Histological grade <0.001
   G1 (well differentiation)  907 (40.1) 155 (14.8)  16 (4.6)  18 (3.2)
   G2 (mod differentiation) 1,182 (52.1) 644 (61.6) 186 (53.8) 157 (27.9)
   G3 (poor differentiation)  177 (7.8) 246 (23.5) 144 (41.6) 387 (68.9)
TNM stage <0.001 
   Stage I 1,563 (69.0)  626 (59.9) 226 (65.3) 351 (62.5)
   Stage II 649 (28.6) 393 (37.6) 112 (32.4) 207 (36.8)
   Stage III  54 (2.4)  26 (2.5)  8 (2.3)  4 (0.7)
Values are presented as mean ± standard deviation or number (%) unless otherwise indicated. 
SLNB, sentinel lymph node biopsy; TNBC, triple negative breast cancer; NPV, negative predictive value; FNR, false negative rate; TA, total 
accuracy; SLN, sentinel lymph node; FSE, frozen specimen examination; ALN, axillary lymph node; IDC, invasive ductal carcinoma; ILC, 
Invasive lobular carcinoma.
Table 5. Subgroup analysis of atypical cells on FSE
Variable Atypical cell (­)a) group (n = 4,190) Atypical cell (+)b) group (n = 29) P­value
FSE results
   False negativec)  153 (3.7) 20 (68.9)
   Accurate FSEd) 4,037 (96.3) 9 (31.1) <0.001
ALN suspicious finding
   ALN suspicious finding (­) 3,412 (81.4) 18 (62.1) 0.012
   ALN suspicious finding (+)  778 (18.6) 11 (37.9)
Histology
   IDC 3,539 (84.5)  20 (69) 0.002
   ILC  202 (4.8)  7 (24.1)
   Other type of carcinoma  449 (10.7)  2 (6.9)
TNM stage
   Stage I 2,760 (65.9)  6 (20.7) <0.001
   Stage II 1,341 (32.0)  20 (69.0)
   Stage III  89 (2.1)  3 (10.3)
Values are presented as number (%). 
FSE, frozen section examination; ALN, axillary lymph node; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
a)Reported “nonmetastatic lymph node” or “metastatic lymph node” during the frozen section examination. b)Reported “atypical cell” 
during the frozen section examination and difficult to designate as nonmetastatic lymph node or metastatic lymph node. These were 
considered non­metastatic lymph nodes. c)Sentinel lymph node reported “free from tumor” during the frozen section examination that 
was changed to “metastasis” in the permanent section examination. d)True­negative + true­positive results.
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frozen section examination is important because this 
determines the decision of additional surgeries, especially for 
patients who require immediate reconstruction or do not meet 
the Z0011 criteria. However, frozen sections are morphologically 
inferior to permanent sections [13]. Moreover, frozen sections 
are difficult to interpret because the applicability of IHC 
for frozen sections is limited. Furthermore, frozen section 
generation can result in permanent tissue loss. In our study, 
patients with confirmed pathologic N2 and N3 stages, for whom 
ALND is mandatory under the Z0011 trial, accounted for less 
than 2% (n = 71) of the patient population. Furthermore, the 
accuracy of frozen section examination is mainly influenced by 
the size of the metastatic node, and secondary further axillary 
surgery should be omitted when only micrometastatic SLNs are 
present with false-negative results due to metastatic nodal size. 
Therefore, the false-negative results due to metastatic node size 
do not change our practice. Our data indicate that intraoperative 
frozen section examination of the SLNs should not be routinely 
performed in all early breast cancer patients. Further in-depth 
studies to identify patients who will benefit from intraoperative 
frozen section should be performed. 
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